16th Jun 2015 07:56
LONDON (Alliance News) - 4D Pharma PLC said Tuesday that it has identified a potential candidate for multiple sclerosis using its biotherapeutic discovery platform MicroRX.
The company has already identified several candidates for severe asthma, allergic asthma and rheumatoid arthritis using MicroRx, and has now identified "that have therapeutically relevant effects in an industry standard model of multiple sclerosis."
Preliminary pre-clinical work showed the prevention of the development of the disease with "demonstrably clear efficacy", 4D Pharma said.
"These results are an exciting development in the progress of live biotherapeutics. To potentially treat a disease such as multiple sclerosis with an oral capsule of therapeutically functional bacteria would be a huge step forward in the treatment of this disease," said Chief Scientific Officer Alex Stevenson in a statement.
Shares in 4D Pharma are trading up 5.2% at 910.00 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
DDDD.L